Healthcare Finance >>>

    Obamacare Shuffles Health Insurance Market Share

    A snapshot of Obamacare enrollment in seven states suggests the law hasn’t significantly increased competition in health insurance markets, the Kaiser Family Foundation reported. Click here to view the entire article.


    Purdue Abuse-Resistant Pill May Cause Zogenix’s Pull

    Purdue Pharma LP plans to apply for regulatory approval of a tamper-resistant competitor to Zogenix Inc.’s powerful pain pill, a move that could get its rival’s drug pulled from the market by U.S. regulators. Click here to view entire article.


    B&G May Borrow for Acquisitions, CEO Says

    B&G Foods may take advantage of low funding rates for debt financed takeovers this year, said CEO David Wenner. Click HERE for more.


    Pfizer Presents Prevnar 13 Data From CAPiTA Trial in Elderly Patients

    by Bloomberg Industries Pfizer is on tap to present data for its vaccine Prevnar 13 from the CAPiTA trial at the International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) on March 12. In a press release issued Feb. 24, the company said that the pneumonia vaccine worked against a first episode of vaccine-type community-acquired pneumonia [...]


    What’s in a Name? Maybe Everything for Biosimilars

    by Brian Rye, Bloomberg Government The Food and Drug Administration’s upcoming guidance on a regulatory pathway for biosimilars may provide clarity on the naming convention for these complex generics. The agency is expected to soon issue more guidance, said Dr. Janet Woodcock, head of the FDA’s Center for Drug Evaluation and Research, at a Bloomberg [...]


    Gender Gap Greater Concern to Insurers Than Low Young Adult Enrollment

    By Sara Hansard Health insurers aren’t alarmed by the relatively low enrollment of young adults in the Affordable Care Act marketplaces, but the heavy concentration of women over men might be a concern, industry consultants told Bloomberg BNA.  Read more >>>


    BioMarin Awaits EU Drug Regulator Review

    by Bloomberg Industries BioMarin’s Vimizim (GALNS, elosulfase alfa) enzyme replacement therapy for the treatment of Mucopolysaccharidosis (MPS) Type IVA (Morquio A syndrome) is among drugs expected to receive an opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) during its February meeting. Decisions are expected on Feb. 20 or [...]


    Wyden’s Chronic Disease Reform Plan Lacks Clear Definition

    A lack of consensus on how to define “chronic disease” could jeopardize bipartisan, bicameral legislation that aims to refocus Medicare service to individuals with multiple chronic and costly conditions. This may be problematic for Sen. Ron Wyden’s legislation, S. 1932, called the “Better Care, Lower Cost Act.” Read more >>>


    Medivation, Astellas May Prevail in Early Stage Prostate Cancer Drug Battle

    Medivation/Astellas will present data on prostate cancer drug Xtandi at the American Society of Clinical Oncology Genitourinary (ASCO GU) event on Jan. 30 that may help with getting doctors to use the drug earlier in treatment. The companies will present an interim analysis of overall survival (OS) and progression free survival (PFS) as well as [...]


    Teva’s Multiple Sclerosis Pill Faces EU Verdict

    by Bloomberg Industries The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) is expected to issue a decision on Teva/Active Biotech’s pill, laquinimod, for relapsing multiple sclerosis (MS). The CHMP meets Jan. 20-23, and will publish its opinions by Jan. 24. Laquinimod is important for Teva because its injectable MS drug [...]


1 2 3 4 7 8 9

Bloomberg BRIEF Newsletters